1.
J Drugs Dermatol
; 16(3): 280-282, 2017 Mar 01.
Article
in English
| MEDLINE
| ID: mdl-28301625
ABSTRACT
Generalized essential telangiectasia (GET) is a notoriously difficult to treat disorder with no current satisfactory treatments. This case and discussion report the use of 6-mercaptopurine (6-MP) as a successful treatment for GET. Moreover, we show that GET may represent a state of increased angiogenesis, a paradigm shift from the current understanding that these telangiectasias represent dilatations of only pre-existing vessels. This new view of GET may drive others to look at novel agents for treatment.
J Drugs Dermatol. 2017;16(3):280-282.
.Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Colitis, Ulcerative/drug therapy , Mercaptopurine/therapeutic use , Neovascularization, Pathologic/urine , Telangiectasis/drug therapy , Antigens, CD34/metabolism , Antimetabolites, Antineoplastic/administration & dosage , Biomarkers/urine , Collagen Type IV/metabolism , Endothelial Cells/metabolism , Female , Fibrinogen/urine , Humans , Lasers, Dye/therapeutic use , Low-Level Light Therapy , Mercaptopurine/administration & dosage , Metalloproteases/urine , Middle Aged , Platelet Endothelial Cell Adhesion Molecule-1/metabolism , Telangiectasis/pathology , Telangiectasis/psychology , Telangiectasis/radiotherapy
2.
